Semaglutide Patent Expiration: 4 Essential Cliff Dates by Market

The single most-asked question about the world’s best-selling drug has a frustrating answer: semaglutide patent expiration is not one date but many. Ozempic and Wegovy already face generics in Canada, India and Brazil in 2026, yet stay protected in the United States until roughly 2032 — and a thicket of formulation and device patents sits behind the compound patent everywhere. Here is the real timeline, market by market, and what it means for prices, generics and the companies planning to enter.

Semaglutide Patent Expiration Is a Country-by-Country Cliff

The reason there is no single semaglutide patent expiration date is that patent term, term extensions and drug classification vary by country. Novo Nordisk’s core protection has already lapsed in several large markets while remaining firmly in force in the most valuable one.

• Canada — main protection expired January 4, 2026; Sandoz has signalled generic discounts of up to 70%.
• India and Brazil — patent lapsed in March 2026, opening the door to domestic generics.
• United States — patent-term extensions keep semaglutide protected until roughly 2032.
• Coverage — India, Canada, China, Brazil and Turkey together hold about 40% of the world’s population.

That split is not an accident of paperwork. It is the product of different patent-term-extension regimes and, crucially, different regulatory classifications — a point we return to below.

The scale of what is opening up is easy to underestimate. Because those five large markets hold roughly a third of the world’s adults living with obesity, the 2026 expiries reshape access for billions of people even while the United States stays closed. For patients, that means far cheaper GLP-1 therapy years earlier than in the US; for manufacturers, it means the first-mover race is already running in Delhi and Toronto, not Trenton.

When Does the Ozempic Patent Expire in the US?

In the United States, the answer runs to about 2032. Multiple patent trackers and Novo Nordisk’s own SEC disclosures put the core US patent (US 8,129,343) and its extensions reaching into the early 2030s. But the compound patent is only the first wall.

Ozempic carries dozens of US drug patents filed between 2018 and 2026 — trackers count 39, of which roughly 19 remain active — covering oral dosing of GLP-1 compounds, solid compositions with absorption enhancers, and the injection pen itself, with expiry dates scattered across 2031, 2034 and 2037. A generic filer must certify against each listed Orange Book patent, not just the molecule.

The Formulation and Device Thicket Behind the Molecule

This is where a headline semaglutide patent expiration date misleads. Even after a compound patent falls, secondary patents on formulation, dosing regimen and the auto-injector can block a specific product for years. A would-be entrant either clears each surviving claim or designs around it.

That is exactly the analysis we walk through in our GLP-1 biosimilar freedom-to-operate case study, where the compound date turned out to be the least useful number in the file — the device and formulation claims decided whether the product could actually launch.

Consider the practical picture. A generic developer that reads only the compound date might tool up for a launch the day protection lapses, only to be enjoined by a live auto-injector or absorption-enhancer claim. The FDA’s February 2025 resolution of the semaglutide shortage — which wound down mass compounding and cleared the way for Novo Nordisk to enforce against compounders — is a reminder that the legal environment tightens the moment supply normalises.

Generics Are Already Live Where the Patent Fell

The commercial effect of the 2026 expiries is not theoretical. In India, at least five domestic drugmakers launched generic semaglutide at up to 80% below the branded price, with Dr. Reddy’s cleared by regulators and Alkem, Biocon and Sun Pharma close behind. In Canada, generic entry followed the January 2026 expiry.

In the US, meanwhile, Novo Nordisk has settled ANDA litigation with a series of generics — Alvogen, Sun Pharma, Dr. Reddy’s, Mylan, Zydus and Apotex among them — each settlement fixing an agreed US entry date rather than opening the market immediately.

Chemical Drug or Biologic? The Classification That Changes Everything

One under-appreciated driver of the split is classification. Canada and Saudi Arabia treat semaglutide as a chemical drug regardless of how it is made, while Brazil, India and South Africa classify it as a biologic. That determines whether a follow-on enters as a generic (an abbreviated filing) or a biosimilar (a comparability programme) — and therefore both the timeline and the patent estate it must clear.

For anyone sizing exposure across markets, that means the same semaglutide patent expiration date can mean a fast generic launch in one country and a multi-year biosimilar development in another.

What It Means for Prices and the GLP-1 Market

The prize is enormous, which is why the patents are contested so hard. For 2030, Goldman Sachs models roughly $95–105 billion in obesity-drug sales, UBS around $130 billion and TD Cowen about $139 billion, while Morgan Stanley sees the wider market near $190 billion by 2035. These are analyst forecasts, not facts — but every one of them assumes falling prices as generics arrive.

The World Health Organization’s 2026 addition of GLP-1 receptor agonists to its Essential Medicines List points the same way: toward volume and price pressure in exactly the markets where the patents have already expired. For a fuller assignee and white-space read, see our GLP-1 patent landscape intelligence page.

The through-line across every forecast is price. As generics arrive market by market, the per-patient cost of semaglutide falls, volume expands, and the revenue mix shifts from a handful of high-price countries toward a much larger, lower-margin global base. That is precisely why the exact timing of each country’s expiry — not a single global date — is the number that decides who captures the upside.

How to Read the Semaglutide Patent Expiration for a Launch

For anyone weighing entry, the useful exercise is to convert the semaglutide patent expiration into a launch calendar rather than a single headline. That means three things done together: fixing the real compound expiry per target market, charting the surviving formulation and device claims in each of those markets, and overlaying the regulatory pathway that classification dictates.

1. Pull the compound expiry per jurisdiction (2026 in Canada, India and Brazil; ~2032 in the US).
2. Chart the live secondary claims — formulation, dosing and device — that survive it.
3. Map the pathway: generic (chemical drug) or biosimilar (biologic), which sets both timeline and register.
4. Set a phased launch that takes the open markets first and holds the US for its later, settled window.

Done properly, that turns a blocked go/no-go into a staged plan — the approach we detail in our GLP-1 biosimilar freedom-to-operate case study.

And Tirzepatide? A Later, Separate Cliff

Eli Lilly’s tirzepatide (Mounjaro and Zepbound) sits years behind. Its GIP/GLP-1 co-agonist molecule patent (US 9,474,780) runs to May 13, 2036, and formulation and method-of-use patents push effective US exclusivity toward 2039. So even after semaglutide opens up, the next blockbuster incretin stays protected well into the 2030s.

Planning Around a Patent Cliff?

PerspireIP maps molecule-by-jurisdiction cliff calendars and freedom-to-operate routes on primary patent data. Explore our GLP-1 patent landscape page or talk to our team about a specific molecule.

Frequently Asked Questions